BioAge Labs

Yahoo Finance • 2 days ago

3 European Growth Companies Boasting Up To 32% Insider Ownership

As European markets experience an upswing, with the pan-European STOXX Europe 600 Index rising by 3% amid hopes for geopolitical de-escalation, investors are keenly observing companies that exhibit both growth potential and significant ins... Full story

Yahoo Finance • 5 days ago

High Growth Tech Stocks In Europe To Watch This May 2026

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index ending the week down amid geopolitical tensions and rising energy costs that could lead to inflationary pressures. Despite these headwinds, rob... Full story

Yahoo Finance • 13 days ago

AMD, Under Armour downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Leerink upgraded Johnson & Johnson(JNJ... Full story

Yahoo Finance • 14 days ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More

Quick Read: The April inflation spike hit stocks hard, as only the Dow Jones Industrial Average finished Tuesday modestly higher. With inflation at its highest level in over 3 years, it’s unlikely the Federal Reserve will cut interest rat... Full story

Yahoo Finance • 22 days ago

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four l... Full story

Yahoo Finance • last month

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial... Full story

Yahoo Finance • 2 months ago

BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)

BioAge Labs Inc. (NASDAQ:BIOA) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 10, Citi maintained a Buy rating on BioAge Labs Inc. (NASDAQ:BIOA). The firm significantly increased its pri... Full story

Yahoo Finance • 2 months ago

BioAge Labs GAAP EPS of -$2.24 beats by $0.08, revenue of $8.99M beats by $1.88M

* BioAge Labs press release [https://seekingalpha.com/pr/20448840-bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-the] (BIOA [https://seekingalpha.com/symbol/BIOA]): FY GAAP EPS of -$2.24 beats by... Full story

Yahoo Finance • 3 months ago

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 6 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 7 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • 8 months ago

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenanc... Full story

Yahoo Finance • 8 months ago

BioAge Labs files $250M mixed securities shelf

* BioAge Labs (NASDAQ:BIOA [https://seekingalpha.com/symbol/BIOA]) files $250M mixed securities shelf. * This prospectus is not an offer to sell these securities. * Filing [https://seekingalpha.com/filing/10487765] MORE ON * Powe... Full story

Yahoo Finance • 8 months ago

BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of lon... Full story

Yahoo Finance • 8 months ago

Leqembi® approved for IV maintenance treatment in China

STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treat... Full story

Yahoo Finance • 8 months ago

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients wi... Full story

Yahoo Finance • 8 months ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

BioArctic has seen a significant price movement of 41% over the past quarter. This surge is closely tied to several positive developments, including an impressive earnings report where the company posted a net income of SEK 96 million, rev... Full story

Yahoo Finance • 9 months ago

BioArctic signs $30 million deal with Novartis for brain drug delivery tech

STOCKHOLM - BioArctic AB (Nasdaq Stockholm:BIOA B), a pharmaceutical company with a market capitalization of $44.9 billion and an "GREAT" financial health rating according to InvestingPro, has entered into an option, collaboration and lice... Full story

Yahoo Finance • 9 months ago

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new trea... Full story

Yahoo Finance • 9 months ago

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story